BioCryst Pharmaceuticals
BCRX
BCRX
290 hedge funds and large institutions have $1.76B invested in BioCryst Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 111 increasing their positions, 84 reducing their positions, and 29 closing their positions.
Holders
290
Holders Change
+18
Holders Change %
+6.62%
% of All Funds
3.89%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
51
Increased
111
Reduced
84
Closed
29
Calls
$12.2M
Puts
$5.49M
Net Calls
+$6.74M
Net Calls Change
+$1.96M
Top Buyers
| 1 |
1
Arrowstreet Capital
Boston,
Massachusetts
|
$38.3M |
| 2 |
2
Assenagon Asset Management
Senningerberg,
Luxembourg
|
$32.4M |
| 3 |
3
UBS Group
Zurich,
Switzerland
|
$50.3M |
| 4 |
4
Morgan Stanley
New York
|
$47.8M |
| 5 |
5
D.E. Shaw & Co
New York
|
$39.3M |
Top Sellers
| 1 |
ACA
1
Avoro Capital Advisors
New York
|
$40.3M |
| 2 |
RM
2
RP Management
New York
|
$0 |
| 3 |
CP
3
Caligan Partners
New York
|
$5.72M |
| 4 |
4
Millennium Management
New York
|
$17.1M |
| 5 |
5
Ameriprise
Minneapolis,
Minnesota
|
$960K |
